Evidence of decreased fibrinolytic activity in hypertensive premenopausal women

References

• Juan-Vague I, Moermann B, De Cock F, Aillaud M F, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Tromb Res 1984; 33: 523–30
   PubMed Web of Science ®Google Scholar
• Hamsten A, Wiman B, deFaire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557–63
   PubMed Web of Science ®Google Scholar
• Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990; 227: 273–8
   PubMed Web of Science ®Google Scholar
• Alessi M C, Juhan-Vague I, Kooistra T, Declerk P J, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemostas 1988; 60: 491–4
   PubMed Web of Science ®Google Scholar
• Vague P, Juhan-Vague I, Aillaud M F, Badier C, Viard R, Alessi M C, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250–3
   PubMed Web of Science ®Google Scholar
• Møller L, Kristensen T S. Plasma fibrinogen and ischemic heart disease risk factors. Arteriosclerosis Thrombosis 1991; 11: 344–50
   PubMed Web of Science ®Google Scholar
• Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501–5
   PubMed Web of Science ®Google Scholar
• Kannel W B, Wolf P A, Castelli W P, D'Agostino R B. Fibrinogen and risk of cardiovascular disease. JAMA 1987; 258: 1183–86
   PubMed Web of Science ®Google Scholar
• Balleisen L, Bailey J, Epping P-H, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in industrual population. I. Baseline data on the relation of age, gender, body-weight, smoking, alcohol, pillusing, and menopause. Thromb Haemost 1985; 54: 475–9
   PubMed Web of Science ®Google Scholar
• de Simone G, Devereux R B, Chien S, Aldermann M H, Atlas S, Laragh J H. Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults. Circulation 1990; 81: 107–7
   PubMed Web of Science ®Google Scholar
• Emery A C, Jr, Whitcomb W H, Frohlich E D. ‘Stress’ polycytemia and hypertension. JAMA 1974; 229: 159–62
   PubMed Web of Science ®Google Scholar
• Göbel B O, Schultze-Göbel A, Weisser B, Glänzer K, Vetter H, Düg R. Arterial blood pressure. Correlation with erythrocyte count, hematocrit, and hemoglobin concentration. Am J Hypertens 1991; 4: 14–9
   PubMed Web of Science ®Google Scholar
• Colditz G A, Willet W C, Stampfer M J, Rosner B, Speizer F B, Hennekens C H. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316: 1105–10
   PubMed Web of Science ®Google Scholar
• Ross R K, Paganini-Hill A, Mack T M, Arthur M, Henderson B E. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1981; 1: 858–60
   PubMed Web of Science ®Google Scholar
• Rostrup M, Mundal H H, Westheim A, Eide L. Awareness of high blood pressure increases arterial plasma catecholamines, platelet noradrenaline and adrenergic responses to mental stress. J Hypertens 1991; 9: 159–66
   PubMed Web of Science ®Google Scholar
• Iatridis S G, Ferguson J H. Effect of physical exercise on blood clotting and fibrinolysis. J Appl Physiol 1963; 18: 337–44
   PubMed Web of Science ®Google Scholar
• Jern C, Eriksson E, Tengborn L, Risberg B, Wadenvik H, Jern S. Changes of plasma coagulation and fibrinolysis in response to mental stress. Thromb Haemost 1989; 62(2)767–71
   PubMed Web of Science ®Google Scholar
• Nordby E, Arnesen H, Andersen P, Godal H C. The euglobulin clot lysis time, a rapid and sensitive method for the assay of fibrinolytic activity after venous stasis. Scand J Hematol 1980; 25: 407–11
   PubMedGoogle Scholar
• Takada A, Takada Y, Urano T, Sakakibara K, Rydzewski A. Fluctuations of euglobulin lysis time, tissue plasminogen activator and free and total plasminogen activator inhibitor levels in plasma in daytime. Thromb Res 1990; 57: 13–20
   PubMed Web of Science ®Google Scholar
• Clauss A. Gerinnungsphysiologische Schnell-methode zur Bestimmungen des Fibrinogenes. Acta hemat. (Basel) 1957; 17: 237–46
   PubMedGoogle Scholar
• Enger S C, Hjermann I, Foss O P, Helgeland A, Holme I, Leren P, Norum K R. High density lipoprotein cholesterol and myocardial infarction or sudden death: a prospective case-control study in middle-aged men of the Oslo city. Artery 1979; 5: 170–81
   PubMedGoogle Scholar
• Burstein M, Scholnick H R, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with poly anions. J Lip Res 1970; 11: 583–95
   PubMed Web of Science ®Google Scholar
• Følling I, Norman N. Hyperglycemia, hypoglycemic attacks and production of anti-insulin antibodies without previous known immunisation. Immunological and functional studies in a patient. Diabetes 1972; 21: 814–26
   PubMed Web of Science ®Google Scholar
• Landin K, Lönnroth P, Krotkiewski M, Holm G, Smith U. Increased insulin resistance and fat lipolysis in obese but not lean women with a high waist/hip ratio. Eur J Clin Invest 1990; 20: 530–5
   PubMed Web of Science ®Google Scholar
• Wing R R, Bunker C H, Kuller L H, Matthews K A. Insulin, body mass index, and cardiovascular risk factors in premenopausal women. Arteriosclerosis 1989; 9: 479–84
   PubMedGoogle Scholar
• Reaven G M. Role of insulin resistance in human disease. Diabetes 1988; 1595–1606
   PubMedGoogle Scholar
• Meade T W, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 1987; 2: 986–8
   PubMed Web of Science ®Google Scholar
• Wallentin L, Larsson-Cohn U. Metabolic and hormonal effects of postmenopausal oestrogen replacement therapy. II. plasma lipids. Acta Endocrinol 1977; 86: 597–607
   PubMedGoogle Scholar
• Lindstedt G, Lundberg P-A, Lapidus L, Lundgren L, Bengtsson C, Bjørnstrop P. Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM. Twelve-year follow up population study of women in Gothenburg, Sweden. Diabetes 1991; 40: 123–8
   PubMed Web of Science ®Google Scholar
• Plymate S R, Fariss B L, Bassett M L, Matej L. Obesity and its role in polycentric ovary syndrome. J Clin Endocrinol Metab 1981; 52: 1246–8
   PubMed Web of Science ®Google Scholar
• Evans D J, Hoffmann R G, Kalkhoff R K, Kissebach A H. Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women. J Clin Endocrinol Metab 1983; 57: 304–10
   PubMed Web of Science ®Google Scholar